A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
Latest Information Update: 28 May 2025
At a glance
- Drugs Avacincaptad pegol (Primary)
- Indications Stargardt disease
- Focus Therapeutic Use
- Acronyms STAR
- Sponsors Astellas Pharma Global Development
Most Recent Events
- 22 May 2025 Status changed from active, no longer recruiting to completed.
- 10 May 2024 Planned End Date changed from 1 Apr 2025 to 30 Apr 2025.
- 10 May 2024 Planned primary completion date changed from 1 Apr 2025 to 30 Apr 2025.